DEPARTMENT OF HEALTH SERVICES
Division of Medicaid Services
F-00805 (01/2021)

STATE OF WISCONSIN
Wis. Admin. Code § DHS 107.10(2)

FORWARDHEALTH

PRIOR AUTHORIZATION DRUG ATTACHMENT FOR MULTIPLE SCLEROSIS (MS) AGENTS, IMMUNOMODULATORS

INSTRUCTIONS: Type or print clearly. Before completing this form, read the Prior Authorization Drug Attachment for Multiple Sclerosis (MS) Agents, Immunomodulators Instructions, F-00805A. Providers may refer to the Forms page of the ForwardHealth Portal at https://www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/ForwardHealthCommunications.aspx?panel=Forms for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization Drug Attachment for Multiple Sclerosis (MS) Agents, Immunomodulators form signed and dated by the prescriber before submitting a prior authorization (PA) request on the Portal, by fax, or by mail. Providers may call Provider Services at 800-947-9627 with questions.

SECTION I – MEMBER INFORMATION

1. Name – Member (Last, First, Middle Initial)

2. Member ID Number

3. Date of Birth – Member

SECTION II – PRESCRIPTION INFORMATION

4. Drug Name

5. Drug Strength

6. Date Prescription Written

7. Refills

8. Directions for Use

9. Name – Prescriber

10. National Provider Identifier – Prescriber

11. Address – Prescriber (Street, City, State, Zip+4 Code)

12. Phone Number – Prescriber

SECTION III – CLINICAL INFORMATION (Required for all PA requests.)

13. Diagnosis Code and Description

14. List the member's current MS agents, immunomodulator therapy or check "None" if appropriate.

❑ None

Drug Name _____ Daily Dose _____ Start Date _____

Drug Name _____ Daily Dose _____ Start Date _____

DT-PA108-108

15. List the member's previous MS agents, immunomodulator therapy and reason(s) for discontinuation or check "None" if appropriate.

❑ None

Drug Name _____ Daily Dose _____ Date(s) Taken _____

Reason for Discontinuation _____

Drug Name _____ Daily Dose _____ Date(s) Taken _____

Reason for Discontinuation _____

Drug Name _____ Daily Dose _____ Date(s) Taken _____

Reason for Discontinuation _____

SECTION IV – CLINICAL INFORMATION FOR NON-PREFERRED ORAL MS AGENTS, IMMUNOMODULATORS (ORAL AGENTS)

16. PA requests must include detailed documentation regarding why the member is unable to take or has previously discontinued Aubagio treatment, Gilenya treatment, and Tecfidera treatment. **Medical records must be provided** to support the need for the non-preferred oral agent. The following will **not** be considered as criteria to support the need for a non-preferred oral agent:
    - Nonadherence to previous MS treatment
    - Member or prescriber preference for the use of a non-preferred oral agent

1. Aubagio Documentation

2. Gilenya Documentation

3. Tecfidera Documentation

SECTION V – CLINICAL INFORMATION FOR KESIMPTA

17. PA requests must include detailed documentation regarding why the member is unable to take or has previously discontinued Gilenya treatment and Tecfidera treatment. **Medical records must be provided** to support the need for Kesimpta. The following will **not** be considered as criteria to support the need for Kesimpta:
    - Nonadherence to previous MS treatment
    - Member or prescriber preference for the use of Kesimpta

    1. Gilenya Documentation

    2. Tecfidera Documentation

SECTION VI – CLINICAL INFORMATION FOR NON-PREFERRED INTERFERONS, MS AGENTS, IMMUNOMODULATORS (INTERFERONS)

18. PA requests for non-preferred interferons must include detailed documentation regarding why the member has previously discontinued **at least two** preferred interferons. **Medical records must be provided** to support the need for the non-preferred interferon. The following will **not** be considered as criteria to support the need for a non-preferred interferon:
    - Nonadherence to previous MS treatment
    - Member or prescriber preference for the use of a non-preferred interferon
    - Member or prescriber preference for a less frequent dosing schedule

    1. Preferred Interferon Documentation

    2. Preferred Interferon Documentation

SECTION VII – CLINICAL INFORMATION FOR GLATOPA

19. PA requests for Glatopa must include detailed clinical justification for prescribing Glatopa instead of the preferred MS agents, immunomodulators Copaxone 20 mg and Copaxone 40 mg. This clinical information must document why the member cannot use Copaxone 20 mg and Copaxone 40 mg, including why it is medically necessary that the member receive Glatopa instead of Copaxone 20 mg and Copaxone 40 mg.

SECTION VIII – AUTHORIZED SIGNATURE	
20. **SIGNATURE** – Prescriber	21. Date Signed

SECTION IX – ADDITIONAL INFORMATION

22. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may be included here.

Reset Form